Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT®) in Pediatric Patients with a Confirmed or Suspected Exposure to Botulinum Neurotoxin

Next Previous
Trial Profile

Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT®) in Pediatric Patients with a Confirmed or Suspected Exposure to Botulinum Neurotoxin

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-antitoxin (Primary)
  • Indications Botulism
  • Focus Pharmacokinetics
  • Sponsors Emergent BioSolutions

Most Recent Events

  • 28 Nov 2022 The study protocol amended to change primary endpoint from calculation of area under the concentration-time curve (AUC 0-24h) to margin of PK equivalence for 90% survival. Maximum age of patient to be enroll changed from 16 years to 11 years. Adolescent population excluded from the study.
  • 15 Nov 2022 Planned number of patients changed from 7 to 10.
  • 15 Nov 2022 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top